Company / Return on Assets (ROA)
Denali Therapeutics Inc. Return on Assets (ROA) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-44.8%
FY2025
5-year range
-44.8% / 4.9%
FY2021-FY2025
Trend
-45.5%
vs FY2024
Sector context
#170 of 213
Health Care
What the data says
Denali Therapeutics Inc.'s return on assets (roa) of -44.8% is lower than 80% of companies in the Health Care sector (FY2025). Return on Assets (ROA) has declined for 3 consecutive years, from 4.9% in FY2022 to -44.8% in FY2025.
Based on SEC 10-K filings.
-44.8% in FY2025 with a 5-year CAGR of -42.5%.
Declined from -12.6% to -44.8% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -49.6pp
- 5-Year Change
- -42.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 213This company -44.8% Sector average -24.2%
▼
-85.3% below sector average
Key checks
Key Insights
- Denali Therapeutics Inc.'s return on assets (roa) has declined for 3 consecutive years.
- In FY2025, return on assets (roa) decreased 45.5% year-over-year.
- Currently 20.6pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -44.8% | -45.5% |
| FY2024 | -30.8% | -144.4% |
| FY2023 | -12.6% | -358.5% |
| FY2022 | 4.9% | +134.6% |
| FY2021 | -14.1% | -522.6% |
| FY2020 | -2.3% | +85.8% |
| FY2019 | -15.9% | -21.8% |
| FY2018 | -13.1% | +27.8% |
| FY2017 | -18.1% | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026